Key facts
- TJ Biopharma’s last known valuation is $459.2M (Sep 2025).
- It has raised $84.2M; the latest was Later Stage VC ($84.2M) in Sep 2025.
- Notable investors include HSG (Hong Kong), CICC Capital, Oriental Fortune Capital, Tailong VC, Heda Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for TJ Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for TJ Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TJ Biopharma
Developer of biotechnology therapies specializing in autoimmune diseases, immuno-oncology, and metabolic disorders. The company's offerings include monoclonal antibody drugs, growth hormone analogues, immunotherapy candidates, biologics manufacturing services and licensing partnerships, enabling accelerated clinical development and commercialisation of innovative treatments for global healthcare markets.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2016
- Website
- tjbio.com/
- Ownership
- Privately Held (backing)
TJ Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TJ Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TJ Biopharma in its N-PORT filings yet. We sweep new filings monthly.